Regenxbio (RGNX) Capital Leases (2018)
Regenxbio's (RGNX) quarterly Capital Leases came in at $5.9 million in Q4 2018.
Regenxbio (RGNX) Capital Leases (2018) Analysis & Trends
Regenxbio's Capital Leases history runs 1 years deep, the most recent figure standing at $5.9 million for Q4 2018.
- On a quarterly basis, Capital Leases changed N/A year-over-year to $5.9 million in Q4 2018; TTM through Dec 2018 was $5.9 million, a N/A change from a year earlier, with the FY2018 full-year figure at $5.9 million, changed N/A from the prior year.
- Capital Leases held at $5.9 million in Q4 2018 per RGNX's latest filing.
- Across five years, Capital Leases topped out at $5.9 million in Q4 2018 and bottomed at $5.9 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Regenxbio | 501.81 Mn | 271.74 Mn | 21.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 5.85 Mn |